title: DPP4 genetic variants influence baseline prostate-specific antigen levels: the J-MICC study.
abstract: Prostate specific antigen (PSA) testing plays a major role in prostate cancer screening; however, the low positive predictive value of PSA testing leads to many unnecessary biopsies. Genetic background is one of factors that could cause it. That's why an association between genetic background and PSA levels should be elucidated. This study aimed to investigate whether DPP4 genetic variants are associated with baseline PSA levels. A cross-sectional study was performed on 2,074 Japanese men aged between 35 and 69 in the Shizuoka area from the Japan Multi-institutional Collaborative Cohort (J-MICC) Study. Three DPP4 tagging single nucleotide polymorphisms (SNPs) were selected for genotyping: rs3788979 (A/G), rs7608798 (T/C), and rs2268889 (A/G). Higher mean serum PSA levels were significantly associated with an increase in the number of the rs7608798 C allele (p for trend = 0.02). A stratified analysis by age groups demonstrated that PSA levels had positive significant trends with the numbers of the minor alleles of rs3788979 or rs7608798 in the oldest group (men aged between 60 and 69) (p for trend=0.004 for rs3788979 and p for trend=0.001 for rs7608798). Haplotype analysis showed that the C-A (rs7608798-rs2268889) haplotype was significantly associated with increased PSA levels (p=0.006), compared with the most common haplotype, T-A. In summary, our study suggests that DPP4 genetic variants influence baseline PSA levels, especially in men aged between 60 and 69.
authors.affiliation: Department of Preventive Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan. h-bata@med.nagoya-u.ac.jp
authors.forename: Takahiro
authors.initials: T
authors.lastname: Higashibata
authors.forename: Mariko
authors.initials: M
authors.lastname: Naito
authors.forename: Atsuyoshi
authors.initials: A
authors.lastname: Mori
authors.forename: Noriyo
authors.initials: N
authors.lastname: Ozawa
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Furuta
authors.forename: Rumi
authors.initials: R
authors.lastname: Tsuchiya
authors.forename: Erina
authors.initials: E
authors.lastname: Koyama
authors.forename: Emi
authors.initials: E
authors.lastname: Morita
authors.forename: Sayo
authors.initials: S
authors.lastname: Kawai
authors.forename: Rieko
authors.initials: R
authors.lastname: Okada
authors.forename: Guang
authors.initials: G
authors.lastname: Yin
authors.forename: Kenji
authors.initials: K
authors.lastname: Wakai
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Hamajima
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D044466:Asian People / Q000235:genetics; D016009:Chi-Square Distribution; D003430:Cross-Sectional Studies; D018819:Dipeptidyl Peptidase 4 / Q000235:genetics*; D005787:Gene Frequency; D006239:Haplotypes; D006801:Humans; D007564:Japan / Q000453:epidemiology; D007610:Kallikreins / Q000097:blood*; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D020641:Polymorphism, Single Nucleotide; D017430:Prostate-Specific Antigen / Q000097:blood*; D015854:Up-Regulation
chemical_list: C042807:DPP4 protein, human; D018819:Dipeptidyl Peptidase 4; C549870:KLK3 protein, human; D007610:Kallikreins; D017430:Prostate-Specific Antigen
references.citation: Jpn J Cancer Res. 2000 Sep;91(9):865-8
references.pmid: 11011111
references.citation: JAMA. 2007 Nov 21;298(19):2275-80
references.pmid: 18029831
references.citation: Urology. 2006 Feb;67(2):316-20
references.pmid: 16442597
references.citation: Diabet Med. 2007 Apr;24(4):333-43
references.pmid: 17367307
references.citation: Am J Hum Genet. 2001 Apr;68(4):978-89
references.pmid: 11254454
references.citation: Lancet. 2003 Mar 8;361(9360):859-64
references.pmid: 12642065
references.citation: Future Oncol. 2009 Sep;5(7):923-6
references.pmid: 19792959
references.citation: J Diabetes Investig. 2010 Oct 19;1(5):212-28
references.pmid: 24843435
references.citation: J Androl. 2000 Mar-Apr;21(2):220-6
references.pmid: 10714816
references.citation: Acta Diabetol. 2009 Mar;46(1):13-21
references.pmid: 18682883
references.citation: Mayo Clin Proc. 2007 Feb;82(2):243-9
references.pmid: 17290734
references.citation: CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
references.pmid: 20610543
references.citation: Bioinformatics. 2005 Jan 15;21(2):263-5
references.pmid: 15297300
references.citation: Prostate. 1997 Dec 1;33(4):225-32
references.pmid: 9397193
references.citation: Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):2035-42
references.pmid: 20696662
references.citation: Am J Epidemiol. 2006 Nov 15;164(10):978-83
references.pmid: 17023544
references.citation: J Natl Cancer Inst. 2003 Jul 16;95(14):1044-53
references.pmid: 12865450
references.citation: Urol Int. 2012;89(1):39-44
references.pmid: 22433834
references.citation: Nat Clin Pract Urol. 2007 Nov;4(11):605-14
references.pmid: 17982437
references.citation: Nagoya J Med Sci. 2009 Sep;71(3-4):137-44
references.pmid: 19994726
references.citation: Asian Pac J Cancer Prev. 2007 Apr-Jun;8(2):317-23
references.pmid: 17696755
references.citation: Cancer Epidemiol Biomarkers Prev. 2001 Jun;10(6):575-9
references.pmid: 11401905
references.citation: Nature. 2003 Dec 18;426(6968):789-96
references.pmid: 14685227
references.citation: Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1350-6
references.pmid: 19383895
references.citation: Prostate. 2009 Mar 1;69(4):419-27
references.pmid: 19116992
references.citation: J Am Board Fam Pract. 2003 Mar-Apr;16(2):95-101
references.pmid: 12665174
references.citation: Diabetes Res Clin Pract. 2010 May;88(2):125-31
references.pmid: 20303610
references.citation: Int J Cancer. 2004 May 10;109(6):855-66
references.pmid: 15027119